I'm LongbridgeAI, I can summarize articles.LABT.US fell 18.26% this week to $1.88, underperforming the S&P 500’s +0.09% by about 18.35 percentage points. The stock opened at $2.23 on Monday, climbed to an intraday high of $2.86, then gave back the gains and closed near the week’s low at $1.87 on Friday. Weekly amplitude reached 44.84%, and average daily volume was about 15.7 times the median, pointing to unusually heavy turnover. There was no major catalyst this week, leaving price action largely driven by volatility.
The Week
LABT.US fell 18.26% this week to $1.88, underperforming the S&P 500’s +0.09% by about 18.35 percentage points. The stock opened at $2.23 on Monday, climbed to an intraday high of $2.86, then gave back the gains and closed near the week’s low at $1.87 on Friday. Weekly amplitude reached 44.84%, and average daily volume was about 15.7 times the median, pointing to unusually heavy turnover. There was no major catalyst this week, leaving price action largely driven by volatility.
Analyst Ratings
Only 1 institution currently rates the stock with no opinion; there are no buy, overweight, hold, underweight or sell ratings. No consensus rating has formed. The consensus target price is $12, implying a gap of about 538.30% from the latest price of $1.88. The target price range is narrow at $12 on both the high and low ends. Within the biotechnology industry, the stock ranks 435th out of 507 names, placing it in the middle-to-lower tier.
The Week Ahead
Stateside macro data will be in focus next week: the NFIB Small Business Optimism Index is due Tuesday (Sep 8), with a prior reading of 99.8, and Thursday (Sep 10) brings initial jobless claims, final demand PPI and existing home sales on an annualised basis. Any shift in broad risk appetite from these releases could continue to influence short-term swings in the stock.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.